CoreCap Advisors’s West Pharmaceutical WST Stock Holding History

CoreCap Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.7K	Buy	91 +13	+17%	+$3.97K	﹤0.01%	1602
2026 Q1	$19.6K	Buy	78 +1	+1%	+$249	﹤0.01%	1678
2025 Q4	$21.2K	Buy	77 +1	+1%	+$274	﹤0.01%	1657
2025 Q3	$20K	Buy	76 +13	+21%	+$3.16K	﹤0.01%	1673
2025 Q2	$13.8K	Sell	63 -15	-19%	-$3.21K	﹤0.01%	1739
2025 Q1	$17.5K	Buy	78 +13	+20%	+$3.58K	﹤0.01%	1598
2024 Q4	$21.3K	Sell	65 -12	-16%	-$3.78K	﹤0.01%	1511
2024 Q3	$23.1K	Buy	+77	New	+$23.6K	﹤0.01%	1488
2024 Q2	–	Sell	-56	Closed	-$22.2K	–	2611
2024 Q1	$22.2K	Buy	+56	New	+$20.7K	﹤0.01%	1434
2022 Q4	$56.2K	Buy	+239	New	+$56.6K	﹤0.01%	952
2022 Q3	–	Sell	-283	Closed	-$86K	–	2119
2022 Q2	$86K	Buy	+283	New	+$92.1K	0.01%	747
2022 Q1	–	Sell	-1,365	Closed	-$640K	–	2116
2021 Q4	$640K	Buy	+1,365	New	+$588K	0.04%	313

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

CoreCap Advisors's WST Position: Q2 2026 in Review

CoreCap Advisors increased its West Pharmaceutical (WST) stake by 17% in Q2 2026, buying an estimated $3.97K and bringing the position to 91 shares worth $32.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1602.

CoreCap Advisors first reported a position in WST in Q4 2021 and has held it in 12 quarters since. The position peaked at $640K in Q4 2021. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

CoreCap Advisors held 91 shares of West Pharmaceutical worth $32.7K as of Q2 2026.
CoreCap Advisors bought 13 West Pharmaceutical shares in Q2 2026, an estimated $3.97K.
West Pharmaceutical made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1602 holding.
CoreCap Advisors first reported a position in West Pharmaceutical in Q4 2021 and has held it in 12 quarters since.
CoreCap Advisors's West Pharmaceutical position peaked at $640K in Q4 2021.
831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.